Ozempic® (semaglutide) doesn’t simply “remove sugar” from your blood. So what is actually happening inside your body? In this Rehealthify video, we take you inside the body to explain how Ozempic works and how semaglutide affects several of the signals involved in blood-sugar regulation. Ozempic is a GLP-1 receptor agonist. Its blood-glucose-lowering effects include stimulating insulin secretion and lowering glucagon secretion when blood glucose is elevated. Semaglutide also causes a delay in early post-meal gastric emptying, which affects how quickly glucose appears in the bloodstream. In this video, you'll see: 🧬 What GLP-1 is and why it matters 💉 How semaglutide activates GLP-1 receptors 🩸 How Ozempic can increase glucose-dependent insulin secretion 🧪 How semaglutide affects glucagon 🫀 Why the liver is part of the blood-sugar story 🍽️ How semaglutide affects early post-meal stomach emptying 🔬 Why Ozempic doesn't simply “remove sugar” from your bloodstream 🧠 How these different signals work together to improve blood-glucose control The goal isn't just to tell you what Ozempic does — it's to help you understand the biology behind the medication. If you take prescription medications, understanding what they do, why they're prescribed, and what questions to ask your healthcare team can be an important part of managing your health. Subscribe to Rehealthify for clear, evidence-based explanations of health conditions, medications, symptoms, and the science behind how your body works. Important Medical Disclaimer This video is provided for general educational and informational purposes only and is not medical advice, diagnosis, or treatment. Ozempic® (semaglutide) is a prescription medication and should be used only as directed by your healthcare professional. Do not start, stop, or change the dose of Ozempic or any other medication based solely on information in this video. If you have questions about your medication, side effects, dosing, interactions, or whether a medication is appropriate for you, speak with your healthcare provider or pharmacist. Ozempic has important warnings and precautions, including a boxed warning concerning thyroid C-cell tumors observed in rodents; it is unknown whether Ozempic causes these tumors in humans. The prescribing information also includes warnings concerning pancreatitis, diabetic retinopathy complications, hypoglycemia when used with certain medications, acute kidney injury, severe gastrointestinal adverse reactions, hypersensitivity reactions, and gallbladder disease. Medical References [1] U.S. Food and Drug Administration / DailyMed Ozempic® (semaglutide) injection — Prescribing Information. Revised May 2026. Includes the medication's indications, mechanism of action, dosing information, warnings, precautions, and adverse reactions. [2] National Library of Medicine / MedlinePlus Semaglutide Injection — Drug Information. Updated May 15, 2026. [3] National Library of Medicine / MedlinePlus Medical Encyclopedia GLP-1 agonists. Information about GLP-1 physiology, insulin, glucagon, gastric emptying, appetite, and potential adverse effects. Trademark Notice: Ozempic® is a registered trademark of Novo Nordisk A/S. Rehealthify is not affiliated with, sponsored by, or endorsed by Novo Nordisk A/S or Novo Nordisk Inc. Keywords Ozempic, Ozempic explained, semaglutide, how Ozempic works, how semaglutide works, GLP-1, GLP-1 receptor agonist, Ozempic mechanism of action, Ozempic blood sugar, Ozempic insulin, Ozempic glucagon, Ozempic stomach emptying, type 2 diabetes medication, diabetes medications, blood sugar control, semaglutide explained, diabetes education, type 2 diabetes, Rehealthify #ozempic #semaglutide #glp1 #type2diabetes #diabetes #diabeteseducation #bloodsugar #medicationsafety #healthinformation #rehealthify